Osteoporosis Clinical Trial
Official title:
Turner Syndrome: Hormone Replacement Therapy
This study will evaluate the effects of hormone replacement therapy on patients with Turner
syndrome (TS)-a genetic disorder in females in which part or all of one X chromosome is
missing. Most girls and women with TS have underdeveloped ovaries-the female reproductive
organs that produce the female sex hormones estrogen and progesterone, and smaller amounts
of the male sex hormone, testosterone. These hormones affect muscle and bone strength, sex
drive, energy, and an overall sense of well being. Estrogen may also play a role in memory
and mood and have a protective effect against heart disease. Women with TS have a much
higher risk of developing osteoporosis (loss of bone density), high blood pressure, high
cholesterol and diabetes than women without this disorder.
Girls and women with Turner syndrome between the ages of 14 and 50 years may be eligible for
this 2-year study. Three months before beginning treatment, all patients will wear an
estrogen patch and take a progesterone tablet daily for 10 days each month. They will then
be randomly assigned to one of two treatment groups to compare the effects of estrogen alone
with estrogen plus testosterone on bone strength, muscle and fat mass and psychosocial well
being. Both groups will wear an estrogen patch and take oral progesterone. One group will
also wear a testosterone patch while the other group will wear a placebo patch (a patch that
does not contain any testosterone). Neither study participants nor the doctors will know who
is getting the testosterone until the study is complete. Patients will undergo the following
procedures before beginning treatment and at 6, 12 and 24 months after starting treatment:
- Physical examination.
- DEXA scans (dual energy X-ray absorptiometry) to measure body composition and bone
thickness. Low radiation X-rays scan the whole body to measure fat, muscle and bone
mineral content..
- Magnetic resonance imaging (MRI) scan of the abdomen to measure the amount of fat
around the internal organs. The patient lies on a stretcher in a large tube surrounded
by a magnetic field during the scanning. The procedure uses a strong magnet and radio
waves to produce the images.
- Heel ultrasound to measure bone thickness. The heel is placed in a chamber and sound
waves pass through it to produce images.
- Oral glucose tolerance test (OGTT) for diabetes and problems with carbohydrate
metabolism. The patient drinks a sugary substance. A small amount of blood is drawn
before taking the drink and four times afterwards.
- Blood and urine tests to measure blood counts, liver and kidney function, ovarian
hormones, growth factors, thyroid function, blood lipids, bone strength markers, and to
test for pregnancy.
- Blood pressure measurements.
- Psychological testing for the effect of treatment on mood, self-esteem, quality of
life, social shyness, anxiety and sexual function.
- Neurocognitive tests (at first inpatient visit and 1 and 2 years after starting
treatment) to measure nonverbal memory and visual-perceptual abilities.
During the hospital admissions, patients will be given a "metabolic diet" that contains
specific amounts of salt and carbohydrates to ensure accurate blood pressure and sugar
metabolism measurements. Patients will keep a record of their menstrual periods and physical
activity throughout the treatment period.
Turner Syndrome (TS) is characterized by ovarian dysgenesis and short stature resulting from the partial or complete deletion of one X-chromosome. Adults with TS have excessive rates of osteoporosis, hypertension, dyslipidemia and diabetes mellitus and may have increased morbidity and mortality as a result. These problems of adults with TS may be secondary to deficiency of ovarian hormones or may result from halpo-insufficiency for as yet unknown X-chromosome genes. There have been no prospective, controlled studies of the effects of hormone replacement therapy (HRT) in TS, but available data suggest that conventional oral HRT designed for postmenopausal women may not prevent osteoporosis and may aggravate hypertension in this disorder. Of note, girls and women with TS are deficient in ovarian androgens as well as estrogen, and have reduced muscle mass, which may contribute to osteoporosis and insulin resistance. In addition, reduced androgens may contribute to the impairment of self esteem and social interactions suffered by many with TS. In this study, two different hormone regimens for TS will be compared in a randomized, placebo-controlled, double-blind design. Both groups will receive transdermal estradiol (E2, 100 mcg/day) with cyclic progesterone; one group will receive a physiological dose of testosterone (T) by transdermal patch while the other group will receive a placebo patch. The treatment duration is 2 years. Major outcome parameters include predicted improvements in bone mineral density, body composition and psychosocial well-being. Essential information will be collected on the effects of hormone treatments on insulin sensitivity and blood pressure in TS. This study will help to optimize hormone replacement treatment for women with TS, and to clarify which of the metabolic problems of TS are secondary to ovarian hormone deficiency, and which are due to genetic factors. ;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Completed |
NCT01401556 -
C-STOP Fracture Trial
|
N/A | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A |